Hyperion Defi (HYPD) Raw Materials (2023 - 2024)
Hyperion Defi (HYPD) posted quarterly Raw Materials of $2.5 million for Q3 2024, up 9748.93% year-over-year from $25790.0 in Q4 2023, and down 8.17% quarter-over-quarter from $2.8 million in Q2 2024.
Hyperion Defi (HYPD) Raw Materials (2023 - 2024) Analysis & Trends
Hyperion Defi (HYPD) has reported Raw Materials for 2 consecutive years, with $2.5 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Raw Materials rose 9748.93% year-over-year to $2.5 million; the TTM figure through Sep 2024 stood at $2.5 million (up 9748.93% YoY), while the FY2023 annual figure was $79115.0, changed N/A from the prior year.
- Raw Materials slipped to $2.5 million in Q3 2024 per HYPD's latest filing, from $2.8 million in the prior quarter.
- Across five years, Raw Materials topped out at $3.1 million in Q1 2024 and bottomed at $25790.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Hyperion Defi | 44.65 Mn | 35.01 Mn | 357,693.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.54 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Mar 31, 2024 | 3.06 Mn |
| Dec 31, 2023 | 79,115.00 |
| Sep 30, 2023 | 25,790.00 |